QIAGEN N.V. announced it will showcase its oncology workflow applications at the American Association for Cancer Research Annual Meeting 2026 in San Diego, demonstrating how its portfolio connects sample preparation with multi-omics profiling and genomic data interpretation to support cancer research and molecular diagnostics. QIAGEN will showcase applications across key stages of the oncology workflow, from sample preparation to genomic profiling and data interpretation. Sample technologies include new instruments and kits highlighting Parse single-cell solutions.
QIAsymphony Connect, the upcoming IVD QIAsymphony Connect, will support oncology workflows in laboratories around the world. This scalable automation platform for clinical molecular testing builds on over 3,300 placements of the established QIAsymphony system to automate IVD sample extraction, improve laboratory productivity, enhance sample traceability and process safety and deliver highly concentrated nucleic acid for sensitive assays. QIAsymphony Connect will help laboratories standardize complex workflows while reducing hands-on time and supporting reproducible, high-quality results.
QIAsprint Connect, following its launch at the SLAS 2026 meeting in February, is now progressing through commercialization as QIAGEN?s new high-throughput automation platform for research laboratories. The compact benchtop system enables automated purification of up to 192 DNA or RNA samples per run, supports validated and customizable workflows, and helps laboratories scale sample processing while reducing plastic use and packaging volume. Parse Biosciences, a QIAGEN company, will highlight at AACR its Evercode Whole Transcriptome portfolio, including the recently launched v4 kit with higher cell recovery, higher sensitivity and shorter workflow with lower sequencing budget.
Parse will also showcase the Evercode Whole Transcriptome FFPE kit, now shipping after the successful completion of an early access program with select partners. The Evercode WT FFPE enables unbiased whole transcriptome single cell RNA sequencing of millions of nuclei from FFPE-preserved tissues using Parse's novel split-pool combinatorial barcoding method. Genomic profiling includes new QIAseq research panels for use on next-generation sequencers.
QIAseq xHYB HRD Panel, developed with Myriad Genetics, is designed to support research into homologous recombination deficiency as an important cancer biomarker for research applications. The assay combines QIAGEN?s hybrid capture technology with Myriad analytics to support assessment of genomic instability, and has shown high concordance with the Myriad myChoice CDx HRD assay. QIAseq xHYB Trinity DNA/RNA Kit enables comprehensive genomic profiling from DNA, RNA or both in a single research workflow using the AVITI platform from Element Biosciences.
Designed for use with Element?s Trinity sequencing workflow, it helps streamline target enrichment through a shorter hybridization step, fewer manual cleanup steps and no post-enrichment PCR, reducing hands-on time while supporting high on-target rates and confident variant detection for research applications. Data interpretation includes the QIAGEN Discovery Platform. QIAGEN Digital Insights, the bioinformatics business of QIAGEN, will introduce the QIAGEN Discovery Platform at AACR as an AI-grounding solution for drug discovery.
The platform is designed to bring together biological knowledge, omics data and advanced analytics to support oncology research, with future implementation of AI functions and integration with downstream AI analysis. The platform will be presented through demonstrations and spotlight sessions at the AACR meeting.
